June 9, 2022 Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Pancreatic Neuroendocrine Carcinoma
January 19, 2022 Panavance Announces Abstract and Poster at ASCO Gastrointestinal Cancers Symposium, Providing an Update on the Status of GP-2250 Clinical Trial in Pancreatic Cancer Patients
